Emiliem, Inc. - Molecularly Targeted Oncology Therapeutics, Multi-Kinase Inhibitor

Emiliem, Inc. Press Release - September 18, 2006

Three Industry Scientists, Bahija Jallal, Manoj Desai, and Sean Ekins, Named to Scientific Advisory Board.

Emiliem, Inc. a biotechnology company that discovers and develops molecularly targeted oncology drugs announced today that three preeminent scientists with extensive drug discovery and development experience have been named to its Scientific Advisory Board. The new appointments include Bahija Jallal, Ph.D., Vice President, Translational Sciences at MedImmune, Inc.; Manoj Desai, Ph.D., Vice President, Medicinal Chemistry at Gilead Sciences; and Sean Ekins, Ph.D., D.Sc., Sr. Vice President, Computational Biology at Arnold Consultancy and Technology LLC. Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem stated, “We are very pleased that these three individuals are joining our SAB at this stage of our company’s life cycle. All three are top scientists in their respective fields, and additionally they all have significant experience in the practical aspects of designing drugs to modulate specific therapeutic targets”.

More information on SAB members can be found on www.emiliem.com

About Us

Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The Company has developed proprietary drug design technologies that facilitate the inclusion of multiple kinase inhibitor profiles into single compounds. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates.

The Company is headquartered in Emeryville, California.



	HOME \| ABOUT \| CORPORATE \| BUSINESS MODEL\| PIPELINE \| PRESS \| NEWS \| CONTACT

	Emiliem, Inc. Press Release - September 18, 2006 Three Industry Scientists, Bahija Jallal, Manoj Desai, and Sean Ekins, Named to Scientific Advisory Board. Emiliem, Inc. a biotechnology company that discovers and develops molecularly targeted oncology drugs announced today that three preeminent scientists with extensive drug discovery and development experience have been named to its Scientific Advisory Board. The new appointments include Bahija Jallal, Ph.D., Vice President, Translational Sciences at MedImmune, Inc.; Manoj Desai, Ph.D., Vice President, Medicinal Chemistry at Gilead Sciences; and Sean Ekins, Ph.D., D.Sc., Sr. Vice President, Computational Biology at Arnold Consultancy and Technology LLC. Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem stated, “We are very pleased that these three individuals are joining our SAB at this stage of our company’s life cycle. All three are top scientists in their respective fields, and additionally they all have significant experience in the practical aspects of designing drugs to modulate specific therapeutic targets”. More information on SAB members can be found on www.emiliem.com About Us Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The Company has developed proprietary drug design technologies that facilitate the inclusion of multiple kinase inhibitor profiles into single compounds. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates. The Company is headquartered in Emeryville, California.